Literature DB >> 22288662

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

Jeffrey L Wolf, David Siegel, Hartmut Goldschmidt, Katharine Hazell, Priscille M Bourquelot, Bourras R Bengoudifa, Jeffrey Matous, Ravi Vij, Margarida de Magalhaes-Silverman, Rafat Abonour, Kenneth C Anderson, Sagar Lonial.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22288662     DOI： 10.3109/10428194.2012.661175

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  57 in total

Review 1.  Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.

Authors:  Salma Afifi; Angela Michael; Mahshid Azimi; Mabel Rodriguez; Nikoletta Lendvai; Ola Landgren
Journal:  Pharmacotherapy       Date:  2015-12       Impact factor: 4.705

2.  A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.

Authors:  S Thomas; R Aggarwal; T Jahan; C Ryan; T Troung; A M Cripps; P Raha; K T Thurn; S Chen; J A Grabowsky; J Park; J Hwang; A Daud; P N Munster
Journal:  Ann Oncol       Date:  2016-02-21       Impact factor: 32.976

3.  Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.

Authors:  Enrique M Ocio; Julio Dávila; Juan-Carlos Caballero; Sara Alonso; Verónica González de la Calle; Ramón García-Sanz; Lucien Gazi; Socrates Opio; Mónica Jiménez; Jesús F San-Miguel; María-Victoria Mateos
Journal:  Haematologica       Date:  2015-03-20       Impact factor: 9.941

4.  Drugs that lack single-agent activity: are they worth pursuing in combination?

Authors:  Bishal Gyawali; Vinay Prasad
Journal:  Nat Rev Clin Oncol       Date:  2017-03-07       Impact factor: 66.675

Review 5.  Seeking Convergence and Cure with New Myeloma Therapies.

Authors:  Priya Choudhry; Derek Galligan; Arun P Wiita
Journal:  Trends Cancer       Date:  2018-06-27

6.  Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma.

Authors:  Donald Moore
Journal:  P T       Date:  2016-05

7.  Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.

Authors:  Sarit E Assouline; Torsten Holm Nielsen; Stephen Yu; Miguel Alcaide; Lauren Chong; David MacDonald; Axel Tosikyan; Vishal Kukreti; Abbas Kezouh; Tina Petrogiannis-Haliotis; Marco Albuquerque; Daniel Fornika; Sepideh Alamouti; Remi Froment; Celia M T Greenwood; Kathleen Klein Oros; Errol Camglioglu; Ayushi Sharma; Rosa Christodoulopoulos; Caroline Rousseau; Nathalie Johnson; Michael Crump; Ryan D Morin; Koren K Mann
Journal:  Blood       Date:  2016-05-10       Impact factor: 22.113

8.  A proposal regarding reporting of in vitro testing results.

Authors:  Malcolm A Smith; Peter Houghton
Journal:  Clin Cancer Res       Date:  2013-04-11       Impact factor: 12.531

9.  Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.

Authors:  Bo Cai; Hui Lyu; Jingcao Huang; Shuiliang Wang; Choon-Kee Lee; Chunji Gao; Bolin Liu
Journal:  Cancer Lett       Date:  2013-02-28       Impact factor: 8.679

Review 10.  Novel approaches to treatment of double-refractory multiple myeloma.

Authors:  Hans C Lee; Jatin J Shah; Robert Z Orlowski
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.